Fortress Biotech, Inc. Aktie News

Der Gesamtumsatz stieg im zweiten Quartal 2026 im Vergleich zum zweiten Quartal 2025 um 14 % auf 18,7 Mio. USD Partnerschaften treiben Programme weiter voran, wobei Crystalys Therapeutics seine Serie-B-Finanzierung in Höhe von 130 Mio. USD ankündigte, um die späte globale Entwicklung und die Vorbereitungen auf die Kommerzialisierung von dotinurad zu unterstützen, und Lizenzgebühren aus den Mark...

MIAMI, 27. Juli 2026 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. („Urica“ oder das „Unternehmen“), eine Tochtergesellschaft von Fortress Biotech, Inc. (Nasdaq: FBIO) („Fortress“), gab heute bekannt, dass Crystalys Therapeutics, Inc. („Crystalys“), an dem Urica eine Beteiligung hält, eine überzeichnete Series-B-Finanzierung in Höhe von 130 Mio. USD abgeschlossen hat, um die globale späte klinis...

SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chi...

MIAMI, May 18, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will pa...

ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million

Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million  Emrosi ® revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position increased to $27 million, driven by strong financial performance Company to hold conference call today at 4:30 p.m. ET SCOTTSDALE, Ariz.